9 Einträge gefunden

1. Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3

   1. Reich, K
   2. Iversen, L
   3. Puig, L
   4. Lambert, J
   5. Mrowietz, U
   6. Kaplan Saday, K
   7. Warren, R B

   2022 - Forschungsinformationssystem des UKE - frei zugänglich
2. Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE-2 and -3

   1. Warren, R B
   2. Hansen, J B
   3. Reich, K
   4. Paul, C
   5. Puig, L

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
3. Time to relapse after tildrakizumab withdrawal in patients with moderate-to-severe psoriasis who were responders at week 28: post hoc analysis through 64 weeks from reSURFACE 1 trial

   1. Warren, R B
   2. Carrascosa, J M
   3. Fumero, E
   4. Schoenenberger, A
   5. Lebwohl, M G
   6. Szepietowski, J C
   7. Reich, K

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
4. Long-term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placebo-controlled studies

   1. Blauvelt, A
   2. Paul, C
   3. van de Kerkhof, P
   4. Warren, R B
   5. Gottlieb, A B
   6. Langley, R G
   7. Brock, F

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
5. Network meta-analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values ≤1, 2, 3 or 5 derived from a statistical conversion method

   1. Mrowietz, U
   2. Warren, R B
   3. Leonardi, C L
   4. Saure, D
   5. Petto, H
   6. Hartz, S
   7. Dossenbach, M

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
6. Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3

   1. Reich, K
   2. Hansen, J B
   3. Puig, L
   4. Konstantinou, M P
   5. Warren, R B

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
7. Long-term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3-year results from two randomized phase III trials (CIMPASI-1 and CIMPASI-2)

   1. Gordon, K B
   2. Warren, R B
   3. Gottlieb, A B
   4. Blauvelt, A
   5. Thaçi, D
   6. Leonardi, C
   7. Poulin, Y

   2021 - Forschungsinformationssystem des UKE - frei zugänglich
8. Long Term Efficacy and Safety of Secukinumab in the Treatment of the Multiple Manifestations of Psoriatic Disease

   1. Reich, K
   2. Warren, R B
   3. Coates, L C
   4. Di Comite, Gabriele

   2020 - Forschungsinformationssystem des UKE
9. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks

   1. Reich, K
   2. Warren, R B
   3. Iversen, L
   4. Puig, L
   5. Pau-Charles, I
   6. Igarashi, A
   7. Ohtsuki, M

   2020 - Forschungsinformationssystem des UKE